As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
|Articles|July 10, 2012
- July 2012 Digestive Health
- Volume 78
- Issue 7
Coffee Consumption and Type 2 Diabetes Risk Reduction
Advertisement
Researchers in Germany investigated the association between coffee consumption and risk for having a heart attack or stroke or developing cancer or type 2 diabetes. Their results were published in the American Journal of Clinical Nutrition.
This study used data from more than 40,000 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC)—Germany study. Coffee consumption was measured via a self-administered questionnaire, and the study had a follow-up period of 8.9 years.
There was no association between coffee consumption and increased risk for any of the investigated diseases. Interestingly, however, investigators found that those who drank 4 or more cups a day of either caffeinated or decaffeinated coffee had a 23% and 30% risk reduction in the development of type 2 diabetes, respectively, compared with those who drank less than 1 cup a day.
To read more articles in this watch, click:
Articles in this issue
about 14 years ago
Deep Breath: Optimizing Selection and Use of Medication Devices in COPDover 14 years ago
Health App Wrapover 14 years ago
Generic Drug Act Awaits Final Approvalover 14 years ago
FDA Policies Source of Drug Shortages, House Committee Reportsover 14 years ago
Generic Product Newsover 14 years ago
Can You Read These Rxs?over 14 years ago
Pet Peevesover 14 years ago
Case Studiesover 14 years ago
Rx Drop Boxes: Do They Work?over 14 years ago
Revocation of Pharmacist's License Reviewed by Appellate CourtAdvertisement
Related to this article
Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
What Different Communities Taught Me About Patient Care
3
Patients Report Early, Sustained Functional Gains With First-Line Zongertinib in HER2-Mutant NSCLC
4
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
5